



CANONIC

Cultivated by Science

A subsidiary of evogene

August 2020

Forward Looking Statement

This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries, including Canonic Ltd. ("Canonic") (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws. Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For these statements, Canonic claims the protection of the safe harbor for forward-looking statements contained in the PSLRA and other securities laws.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Canonic and Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Canonic's and Evogene's control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information it files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Canonic and Evogene disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.


The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

Our Mission


Commercialize precise & stable medical cannabis products for better therapeutic effects

Market

Legal market estimated at ~\$104B in 2024




Medical market estimated at ~\$62B in 2024



Source : Cannabis global report , prohibition partners Nov 2019, numbers in graph are rounded

The opportunity and gap

Addressing phenomenal market growth (14% in US only) will require to overcome significant market challenges



Source: New frontier data (US only)

Key Market Challenges



SPECIFICITY

Specific medical indications require tailored active compound profiles. To date, breeding mainly pushed THC levels






YIELD

Legalization is driving steep declines in market prices, giving advantage to high yield products



STABILITY

Substantial variations within varieties produce inconsistent products and therefore inconsistent results




Canonic tackles the market challenges...


Our solution

Based on established world-class genomic expertise and technology we seek to create specific genomic profiles to address market challenges – specificity, yield and stability.

Current cannabis genetic mapping



Canonic: seeing the bigger picture



Cannabis – an optimal crop for our solution



Fact 1

Cannabis has been caught in a time capsule with no access to innovation and technologies

Small intervention - huge impact

Fact 2

Cannabis can be grown for at least 3 growth cycles in a year

Triple development speed

Fact 3


Cannabis is grown in a controlled environment

Consistent performance

We believe Canonics technology platform enable fast & efficient, non-GMO product development

Mission execution


Canonic aims to quickly and cost effectively reach the end user, by leveraging proprietary genomic expertise and outsourcing elements of the value chain.



Variety development through advanced breeding,
seed production and seedling production,
will be conducted in-house,
while cultivation, formulation and distribution are expected to be conducted through partnerships.

Our business strategy

Quickly and cost effectively reach the end user, by leveraging proprietary genomic expertise and outsourcing downstream elements of the value chain.



Product types

MetaYield⁺

Stable enhancement of
total plant compounds



Category 3:
Increased compounds/plant
[e.g. Increased trichomes prevalence]



Category 4:
Increased compounds/area
[e.g. Dwarf - early flowering]

Precise⁺

Stable enhancement of
specific active compounds



Category 1:
Medical indication focus
[e.g. Pain/inflammation]



Category 2:
Compound profile focus
[e.g. CBG/CBC]

MetaYield+ Products



Category 3: Increased compounds/plant

WILD TYPE



MODIFIED TYPE



Active compounds concentration is effected by the trichome population, we have proprietary IP for **trichome enhancement**

✓ **Market Value- \$5B***

10% increase in trichome prevalence can increase revenue per acre by >\$1.9M

Category 4: Increased compounds/area

WILD TYPE



MODIFIED TYPE



Yield per area is affected by plant architecture, we have proprietary knowhow for plant morphology and dwarfing

✓ **Market value - \$3.5B***

10% annual yield increase (add. 2 cycles/y) can increase annual revenue per acre by >1.3M\$

*Based on 10% yield increase at 2500-acre estimation and market forecast by Prohibition Partners Nov 2019.

Initiation of Cultivation & Breeding Program



Canonix Announces Initiation of Cultivation and Breeding of Cannabis Varieties with Unique Genomic Profiles for the Development of Medical Cannabis Products


This announcement follows successfully importing a collection of widely genetically diverse cannabis lines, establishing specialized R&D facilities, and receiving regulatory approval from the Israeli Medical Cannabis Agency (IMCA)

Rehovot, Israel – November 6, 2019 – Canonix, a wholly owned subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN) focused on the development of medical cannabis products, announces today the initiation of its cultivation and breeding program of cannabis varieties with unique genomic profiles for the development of medical cannabis products. The initiation of cannabis cultivation follows: (1) successfully importing widely genetically diverse cannabis lines originating from different territories, (2) establishment of cannabis dedicated R&D facilities, including greenhouses, a molecular lab and tissue culture rooms and (3) receipt of the required regulatory approvals from the Israeli Medical Cannabis Agency (IMCA).

Precise⁺ Products



Category 1: Medical indication focus




We use pre-clinical trials to guide our breeding program to specific medical indications

✓ **Market value - \$16B***

Medical cannabis is anticipated to reach 10% of the \$160B Chronic Pain and Inflammation market

*Based on 10% of the current pain management and inflammation market (Visual Capitalist data).

Category 2: Compound profile focus



We identify specific minor cannabinoids and optimize their biosynthesis *in planta*

✓ **Market valuse- \$15B****

CBG is priced at 200\$ per gr.
At 5% CBG the revenue per acre is 17.5M\$

**Estimating those cannabinoids will reach 60% of the comparable CBD market in 2025 (A.G.P. Market survey).

Agreement for Pre-Clinical Studies




Canonix Announces an Agreement with Hadassah Medical Center for Pre-Clinical Studies to Support the Development of Canonix's Medical Cannabis Products

The studies will focus on inflammatory indications at Prof. Reuven Or's laboratory

Rehovot, Israel – January 27, 2020 – Canonix, a wholly owned subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN) focused on the development of medical Cannabis products, announces today an agreement with Hadasit, Hadassah Medical Center Technology Transfer Company, for pre-clinical studies to support the development of anti-inflammatory medical Cannabis products as part of its *Precise* product program. The work will be conducted by the laboratory of Prof. Reuven Or in Hadassah Medical Center (Ein Kerem, Israel), screening Canonix's Cannabis core collection in inflammatory in-vitro models. These studies are expected to support the development of Canonix's unique Cannabis varieties with anti-inflammatory properties.


What do we need to lift the curtain?



Technology, Know-how & Advanced Breeding

All under one roof

Canonic holds exclusive access to assets along the entire innovation value chain for improved varieties development



"Innovation will transform the cultivation, processing, sale, and consumption of cannabis in legal markets" (New Frontier Data 2019)

Harnessing IP and Data



An immense IP portfolio




Within the top 10 companies in the world* holding plant genetics know how & IP

* <https://www.lens.org/>




High quality tailored data



- > 200 plant species
- > Dozens of Cannabis lines
- > 3*10⁹ data points
- > 1000 experiments
- > 10 Omic data types

Multilayer Hubs



- Genome
- Transcriptome
- Chemotype
- Phenotypes
- Clinical data

Applying cutting-edge Computational Power



**ARSENAL OF COMPUTATIONAL
TOOLS AND AI APPLICATIONS
APPLIED TO CANNABIS**

**USING AI TO IDENTIFY GENETIC
ELEMENTS THAT YIELD DESIRED TRAITS**



Developing in Israel's top cannabis R&D facilities



**22,000 square feet
of greenhouses**



**internal seed
quarantine facility**



**Operating under
the Israeli Medical
Cannabis Agency**



**dedicated tissue
culture facility**



**fully equipped
molecular labs**



Partners and collaborators

Data & Computational



Clinical validation



Commercial partners



PORTOCANNA



Canonic's team

Management



Dr. Arnon Heyman
CEO

Former VP and GM Ag seeds division
Evogene, CTO BondX technologies



Ofer Haviv
Chairman of the board

Evogene CEO and President



Dr. Inbal Dangoor
Head of R&D

Former Biotech Trait Manager,
Ag seeds division Evogene



Dorit Kreiner
CFO

Former Chief Financial Officer in
Therapix (TASE: THXY) and NRGene

Advisory board



Dr. Yossi Tam
Cannabinoid clinical research

Director, Multidisciplinary Center for
Cannabinoid Research of the Hebrew
University



Dr. Yariv Brotman
Plant metabolic pathways

Ben Gurion University & Max Planck
institute of Molecular Plant Physiology



Dr. Moshe Bar
Plant breeding

Former Global Head of Scouting and
Strategic Projects at Syngenta and VP
R&D at Zeraim Gedera


Milestones Roadmap

2020

- Demonstrate yield improvement in cannabis lines under development.
- Engagement with commercial partners for cultivation and production.
- Conduct pre-clinical studies to support the development of Canonic's medical cannabis products.

2021

- Pre-commercial activity with first cannabis variety towards commercialization in 2022.
- Demonstrate clinical effects of Canonic varieties based on dedicated research with a medical institution.



Summary

Canonic seeks to develop and bring to market medical grade Cannabis through a revolutionary genomic approach

Go-To-Market – 5 frame agreements signed with commercial partners for cultivation and production in Israel and Europe

Commercialization during 2022

Using computational power (Artificial Intelligence, Big Data) to develop **Two product lines:**

(I) Stable enhancement of specific active compounds (II) Stable enhancement of total plant compounds

Exclusive access to **Evogene's CPB technology platform, IP and infrastructure** for the development of medical cannabis products



CANONIC

THANK YOU